Evotec SE Adjusts FY25 Revenue Guidance; Adj. EBITDA Outlook Remains Unchanged

Evotec SE (EVO) has lowered its fiscal year 2025 Group revenue guidance to €760-800 million from the previous €840-880 million, attributing the revision to a change in revenue mix and significant cost savings exceeding initial targets from its Priority Reset initiative. Despite this downward adjustment to top-line expectations, the company's guidance for R&D expenses and adjusted EBITDA remains unchanged. This guidance update follows first-half 2025 revenues that were below expectations, although adjusted EBITDA was broadly in line.

Analysis

Evotec SE (EVO) has materially revised its fiscal 2025 revenue guidance downward to a range of €760-800 million from the prior €840-880 million. The company attributes this reduction to a change in revenue mix and significant cost savings achieved through its 'Priority Reset' initiative that exceeded initial targets. Critically, despite the top-line weakness, which was foreshadowed by below-expectation revenues in the first half of the year, guidance for both R&D expenses and adjusted EBITDA remains unchanged. This implies that management expects the combination of a more favorable margin mix and aggressive cost controls to fully offset the impact of lower sales, thereby preserving the company's core profitability outlook for the fiscal year.

Key Decisions for Investors

• Investors should adjust their top-line growth models downward to reflect the new, lower revenue forecast, which signals a significant shift in near-term sales expectations.
• The reaffirmed adjusted EBITDA guidance is the key mitigating factor; focus should be placed on the company's execution and ability to maintain margins despite the revenue shortfall.
• It is prudent to scrutinize future management commentary for details on the new revenue mix and the sustainability of the cost savings from the 'Priority Reset' to determine the long-term impact on profitability.